IndustryCompany release

Collegium reports record Q3 revenue of $216.3M as JORNAY PM sales rise 24%

🇺🇸 Collegium Pharmaceutical, Inc (COLL) · Thu 05 Nov 2026

Growth in the ADHD portfolio offset an 18% fall in pain products, and the company reaffirmed its 2026 guidance.

Collegium Pharmaceutical reported third-quarter 2026 results on 5 November. Net product revenue rose 3% to $216.3M, which the company described as a record for a third quarter.

JORNAY PM generated $51.9M, up 24%. AZSTARYS contributed $26.5M in its first full quarter under Collegium ownership. The summary of the release gives no further detail on how the product was acquired or on its earlier sales.

The pain portfolio moved in the opposite direction, falling 18% to $138.0M. The figures point to a business shifting its revenue mix towards ADHD treatments as pain sales decline.

Collegium also reaffirmed its 2026 financial guidance and a $50M accelerated share repurchase. The material available gives no specific guidance figures or repurchase terms.

What it means for your team

  • Collegium's revenue mix is moving from pain products towards ADHD medicines, with JORNAY PM and AZSTARYS now a larger share of sales.
  • Teams tracking the pain market should note the 18% decline in Collegium's pain portfolio sales in the quarter.
  • The reaffirmed 2026 guidance suggests the company expects no change to its full-year outlook, though the guidance figures were not in the material reviewed.

Company's press release (SEC filing): Collegium Pharmaceutical, Inc ↗

Article written by VigiEye from the official source (Collegium Pharmaceutical, Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →